이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Applied DNA Sciences 관리

관리 기준 확인 4/4

Applied DNA Sciences' CEO는 James Hayward, Apr2006 에 임명되었습니다 의 임기는 18.17 년입니다. 총 연간 보상은 $ 468.00K, 96.2% 로 구성됩니다. 96.2% 급여 및 3.8% 보너스(회사 주식 및 옵션 포함). 는 $ 3.05K 가치에 해당하는 회사 주식의 0.066% 직접 소유합니다. 3.05K. 경영진과 이사회의 평균 재임 기간은 각각 9.3 년과 8.3 년입니다.

주요 정보

James Hayward

최고 경영자

US$468.0k

총 보상

CEO 급여 비율	96.2%
CEO 임기	18.2yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	9.3yrs
이사회 평균 재임 기간	8.3yrs

최근 관리 업데이트

Recent updates

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Dec 20

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Aug 17

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise

Aug 09

Applied DNA stock soars 73% on starting validation of PCR-based monkeypox test

Aug 02

Applied DNA announces positive data from veterinary vaccine trial to treat COVID-19

Jul 25

News Flash: Analysts Just Made A Notable Upgrade To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

May 18

Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Deliver On Growth Plans?

Sep 17

CEO 보상 분석

James Hayward 의 보수는 Applied DNA Sciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	n/a	n/a	-US$7m
Sep 30 2023	US$468k	US$450k	-US$10m
Jun 30 2023	n/a	n/a	-US$7m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	n/a	n/a	-US$7m
Sep 30 2022	US$2m	US$450k	-US$8m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	n/a	n/a	-US$14m
Sep 30 2021	US$1m	US$400k	-US$14m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	n/a	n/a	-US$15m
Sep 30 2020	US$451k	US$133k	-US$13m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	n/a	n/a	-US$8m
Sep 30 2019	US$375k	US$233k	-US$9m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	n/a	n/a	-US$12m
Sep 30 2018	US$481k	US$250k	-US$12m
Jun 30 2018	n/a	n/a	-US$11m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	n/a	n/a	-US$12m
Sep 30 2017	US$546k	US$282k	-US$13m

보상 대 시장: James 의 총 보상 ($USD 468.00K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 683.56K ).

보상과 수익: James 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

James Hayward (70 yo)

18.2yrs

테뉴어

US$468,000

보상

Dr. James A. Hayward, Ph D., Sc D., has been Chief Executive Officer and Chairman of Applied DNA Sciences, Inc. (Formerly Known as Prohealth Medical Tech, Inc) since March 17, 2006 and since June 12, 2007...

리더십 팀

이름	위치	테뉴어	보상	소유권
James Hayward	Chairman	18.2yrs	US$468.00k	0.066% $ 2.7k
Beth Jantzen	Chief Financial Officer	9.3yrs	US$501.00k	0.020% $ 837.3
Judith Murrah	COO, Chief Information Officer & Secretary	11yrs	US$542.75k	0.023% $ 954.6
Clay Shorrock	Chief Legal Officer & Executive Director of Business Development	3.2yrs	US$501.00k	0.027% $ 1.1k
Sanjay Hurry	Executive Director of Investor Relations & Corporate Communications	3.9yrs	데이터 없음	데이터 없음

9.3yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: APDN 의 관리팀은 노련하고 경험 (평균 재직 기간 9.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
James Hayward	Chairman	18.8yrs	US$468.00k	0.066% $ 2.7k
Robert Catell	Chairman of Strategic Advisory Board & Independent Director	8.3yrs	US$152.50k	0.00095% $ 39.6
Yacov Shamash	Independent Director	18.3yrs	US$162.50k	0.00077% $ 32.1
Raymond Kelly	Member of Strategic Advisory Board	7.4yrs	데이터 없음	데이터 없음
Joseph Ceccoli	Independent Director	9.5yrs	US$155.00k	0.00027% $ 11.3
Sanford Simon	Independent Director	18.3yrs	US$151.25k	0.000040% $ 1.7
Mehmood Khan	Member of Strategic Advisory Board	7.7yrs	데이터 없음	데이터 없음
Gunther Faber	Member of Strategic Advisory Board	8.3yrs	데이터 없음	데이터 없음
Elizabeth M. Shaheen	Independent Director	7yrs	US$153.75k	0.00038% $ 15.9
Stephen Birkhold	Member of Strategic Advisory Board	5.4yrs	데이터 없음	데이터 없음

8.3yrs

평균 재임 기간

73yo

평균 연령

경험이 풍부한 이사회: APDN 의 이사회는 경험(평균 재직 기간 8.3 년)으로 간주됩니다.

Applied DNA Sciences 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

Insufficient new directors

Applied DNA Sciences, Inc. Announces Retirement of John Bitzer from Board of Directors

Recent updates

Consensus EPS estimates upgraded to US$5.32 loss

Applied DNA Sciences, Inc. Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

New major risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

Consensus estimates of losses per share improve by 24%

Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.

Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Consensus revenue estimates fall by 49%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq

Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023

Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

New minor risk - Share price stability

Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million.

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023

Consensus revenue estimates increase by 12%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023

Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines

Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 20%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to US$7.00

Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022

Applied DNA climbs 51% after winning large purchase order

Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service

Applied DNA stock rises 12% on launching monkeypox testing service in New York

Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Applied DNA adds 17% as company seeks approval for monkeypox test in New York

Consensus estimates of losses per share improve by 19%

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise

Price target decreased to US$5.00

Applied DNA stock soars 73% on starting validation of PCR-based monkeypox test

Applied DNA Sciences, Inc. Announces Retirement of John Bitzer from Board of Directors

Applied DNA announces positive data from veterinary vaccine trial to treat COVID-19

Applied DNA Sciences, Inc. Launches Initiatives to Expand Awareness of LinearDNA Platform as Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website

Applied DNA and Evvivax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA Platform

Consensus revenue estimates increase by 20%

News Flash: Analysts Just Made A Notable Upgrade To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences, Inc. to Report Q2, 2022 Results on May 12, 2022

Price target decreased to US$12.00

Applied DNA Sciences, Inc. and EvviVax, S.R.L. Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy